SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-001993
Filing Date
2024-01-04
Accepted
2024-01-04 08:45:31
Documents
14
Period of Report
2023-12-28
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d105742d8k.htm   iXBRL 8-K 34737
2 EX-99.1 d105742dex991.htm EX-99.1 9838
6 GRAPHIC g105742g0103093118074.jpg GRAPHIC 8518
  Complete submission text file 0001193125-24-001993.txt   183579

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigr-20231228.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20231228_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20231228_pre.xml EX-101.PRE 11262
8 EXTRACTED XBRL INSTANCE DOCUMENT d105742d8k_htm.xml XML 3424
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 24509854
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)